MA43981A - Formulations à base de fluoroquinolone pour le traitement de la mucoviscidose - Google Patents

Formulations à base de fluoroquinolone pour le traitement de la mucoviscidose

Info

Publication number
MA43981A
MA43981A MA043981A MA43981A MA43981A MA 43981 A MA43981 A MA 43981A MA 043981 A MA043981 A MA 043981A MA 43981 A MA43981 A MA 43981A MA 43981 A MA43981 A MA 43981A
Authority
MA
Morocco
Prior art keywords
mucoviscidosis
treatment
fluoroquinolone formulations
fluoroquinolone
formulations
Prior art date
Application number
MA043981A
Other languages
English (en)
French (fr)
Inventor
Donald Vandervanter
Original Assignee
Horizon Orphan Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Orphan Llc filed Critical Horizon Orphan Llc
Publication of MA43981A publication Critical patent/MA43981A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA043981A 2016-02-05 2017-02-02 Formulations à base de fluoroquinolone pour le traitement de la mucoviscidose MA43981A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662292065P 2016-02-05 2016-02-05
US201662293554P 2016-02-10 2016-02-10
US201662348439P 2016-06-10 2016-06-10

Publications (1)

Publication Number Publication Date
MA43981A true MA43981A (fr) 2018-12-12

Family

ID=59500283

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043981A MA43981A (fr) 2016-02-05 2017-02-02 Formulations à base de fluoroquinolone pour le traitement de la mucoviscidose

Country Status (5)

Country Link
US (1) US20210113579A1 (enExample)
EP (1) EP3411503A4 (enExample)
JP (2) JP6966835B2 (enExample)
MA (1) MA43981A (enExample)
WO (1) WO2017136516A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102325532B (zh) 2008-10-07 2015-06-17 Mpex医药有限公司 用于减轻肺部炎症的左氧氟沙星吸入剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080394B2 (en) * 2007-04-27 2011-12-20 Brigham And Women's Hospital Method for determining predisposition to pulmonary infection
CN102325532B (zh) * 2008-10-07 2015-06-17 Mpex医药有限公司 用于减轻肺部炎症的左氧氟沙星吸入剂
KR20120034626A (ko) * 2009-04-24 2012-04-12 엠펙스 파마슈티컬즈, 인코포레이티드 플루오로-퀴놀론을 사용하여 폐의 세균성 감염을 치료하는 방법
LT2473170T (lt) * 2009-09-04 2019-10-10 Horizon Orphan Llc Aerozolizuoto levofloksacino panaudojimas cistinės fibrozės gydymui

Also Published As

Publication number Publication date
EP3411503A4 (en) 2019-11-27
JP2017137289A (ja) 2017-08-10
US20210113579A1 (en) 2021-04-22
JP2022028674A (ja) 2022-02-16
JP6966835B2 (ja) 2021-11-17
EP3411503A1 (en) 2018-12-12
WO2017136516A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3448875A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) COMPOSITIONS FOR TREATING A DISEASE
MA45192A (fr) Traitement d'association
PT3523390T (pt) Utilização de composições à base de tetrafluoropropeno
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
EP3370703A4 (en) GEMCABEN COMBINATIONS FOR TREATING HEART CIRCULATION DISEASES
EP3377068A4 (en) COMBINATION THERAPY OF TETRACYCLIC CHINOLONANALOGES FOR THE TREATMENT OF CANCER
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3374350A4 (en) HYDROXYPYRIDINONE- AND HYDROXYPYRIMIDINONE-BASED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
MA42999A (fr) Polythérapie pour le traitement de malignités
EP3463341A4 (en) AMINOACYLINDOL IMMUNOMODULATORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP3335041A4 (en) BIOMARKER FOR THE TREATMENT OF ALOPECIA AREATA
EP3437540A4 (en) ENDOSKOP HOLDER
EP3630196A4 (en) COMBINATION THERAPIES FOR TREATMENT OF CANCER
EP3328864A4 (en) THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF SOCIAL DISORDERS AND DRUG ABUSE
EP3490561A4 (en) COMBINATIONS FOR TREATING CANCER
EP3344325A4 (en) LOCAL ADMINISTRATION OF MEDICAMENTS FOR THE TREATMENT OF ASTHMA
EP3443962A4 (en) Quinoline derivative for the treatment of gastric cancer
EP3316887A4 (en) GLS1-INHIBITOR TO TREAT DISEASES
EP3349793A4 (en) ANTI-S100A8 FOR THE TREATMENT OF LEUKEMIA
EP3503887A4 (en) COMBINATIONS FOR TREATING CANCER
EP3307301A4 (en) FOCUSED INTERFERON IMMUNOTHERAPY FOR THE TREATMENT OF CANCER